AL Amyloidosis Presenting With Chronic Gastrointestinal Symptoms in a Patient With Lymphoplasmacytic Lymphoma Authors: Sima Fansa, Abdelwahab Ahmed, Mahdi Osman, Hussam Kawas, Scott Robertson, Syed Mohiuddin Published: 2026 ABSTRACT ABSTRACTAmyloidosis is a heterogeneous group of disorders caused by extracellular deposition of misfolded proteins, leading to organ dysfunction. Gastrointestinal involvement is common but often under-recognized, and presentations vary widely depending on the amyloid subtype. We present a case of a 68-year-old man with chronic gastrointestinal symptoms, ultimately diagnosed with AL amyloidosis associated with lymphoplasmacytic lymphoma. Management included chemotherapy and supportive measures for the gastrointestinal symptoms. This case highlights the importance of considering amyloidosis in patients with chronic gastrointestinal symptoms, particularly in the setting of plasma cell dyscrasias. INTRODUCTION Amyloidosis is a group of diseases caused by the extracellular deposition of abnormally folded proteins in various body tissues leading to organ dysfunction.1 There are different types of amyloidosis depending on the type of protein that accumulates, with the most common being amyloid light-chain amyloidosis (AL) amyloidosis, amyloid A (AA) amyloidosis, and transthyretin (ATTR) amyloidosis. Most patients with amyloidosis require a biopsy of an involved tissue to confirm the diagnosis. Symptoms depend on the type and organ involvement of the amyloid deposits. While the kidney and heart are the most involved organs, amyloid tends to also deposit in the gastrointestinal (GI) tract.2 The presence and pattern of GI symptoms varies substantially.3 GI amyloidosis predominantly affects men with a median age at diagnosis of 61-68 years.4,5 Approximately 21% of biopsy-proven GI amyloidosis cases represent localized disease without systemic involvement.6 GI amyloidosis should be suspected even in the absence of a family history, as most cases are attributable to AL or wild-type ATTR amyloidosis, which are acquired rather than inherited forms of the disease.7 Therapy should be carefully tailored based on severity of organ involvement and the identity of the amyloidogenic protein.8 For AL amyloidosis, chemotherapy and stem cell transplantation are considered gold standard.9 We present a 68-year-old man with chronic GI symptoms who was ultimately diagnosed with AL amyloidosis associated with lymphoplasmacytic lymphoma and cardiac involvement. CASE REPORT A 68-year-old man with a history of chronic GI symptoms including diarrhea, constipation, and flatulence, presented for further evaluation of his symptoms. Over the preceding year, his symptoms had worsened, and he reported unintentional weight loss along with new-onset lower extremity edema. His medical history was notable for small intestinal bacterial overgrowth, benign prostatic hyperplasia, and major depressive disorder. Previous EGD/colonoscopy were significant for mild gastritis. His surgical history included rotator cuff repair, septoplasty, and inguinal hernia repair. His medications consisted of vitamin supplementation. The patient denied any family history of GI disease, autoimmune disorder or malignancy. Upon presentation, a push enteroscopy demonstrated diffuse nodular and edematous mucosa enlarged white villi throughout the duodenum and jejunum, along with scalloping and fissuring of the mucosa. Histopathologic examination of duodenal and jejunal biopsies revealed accumulation of proteinaceous material within dilated villi. Congo red staining demonstrated no evidence of amyloid deposition. Flow cytometry was negative for lymphomatous involvement. Additional immunohistochemical studies of the small bowel biopsy revealed foamy macrophages within the lamina propria while excluding carcinoma, the Whipple disease, and celiac disease (Figure 1). These abnormalities were thought to contribute to protein-losing enteropathy, likely explaining his weight loss and edema. Work-up revealed elevated M protein and IgM, and bone marrow biopsy confirmed lymphoplasmacytic lymphoma, for which he was initiated on bendamustine and rituximab. Nodular, edematous mucosa with white villi, scalloping, and fissuring in the second portion of duodenum (A) and jejunum (B). A capsule endoscopy was performed to assess disease involvement and it demonstrated mucosa studded with innumerable white nodules throughout the duodenum and jejunum. The patient started experiencing a worsening in functional capacity and new-onset dyspnea, with further evaluation confirming cardiac amyloidosis on endomyocardial biopsy. The patient was placed under evaluation for heart transplant and as part of the evaluation, push enteroscopy and colonoscopy revealed patchy erythematous mucosa in the gastric antrum and progression of previously noted findings including diffuse nodular mucosa with enlarged whitish villi throughout the duodenum and proximal jejunum (Figure 2). Biopsies obtained from the stomach, duodenum, and jejunum demonstrated amyloidosis (Figure 3). The patient was subsequently started on zanubrutinib for the management of his lymphoplasmacytic lymphoma and received supportive care for his GI symptoms. Diffuse nodular mucosa with enlarged whitish villi throughout the second portion of duodenum (A) and proximal jejunum (B). Gastric biopsies (10×) demonstrating amyloid deposition with hematoxylin and eosin stain (A) and Congo red stain (B) consistent with gastrointestinal amyloidosis. He reported significant improvement in his GI discomfort symptoms. DISCUSSION The differential diagnosis of chronic diarrhea, constipation, and flatulence is broad and includes, but is not limited to, irritable bowel syndrome, inflammatory bowel disease, malabsorption syndromes, small intestinal bacterial overgrowth, malignancy and medication adverse effects. In this case, worsening gastrointestinal symptoms and unintentional weight loss prompted further investigation for an underlying cause. After lymphoplasmacytic lymphoma was diagnosed and cardiac MRI suggested amyloidosis, there was suspicion for amyloidosis with gastrointestinal involvement, which was ultimately confirmed by biopsy. AL amyloidosis is the most common subtype of amyloidosis and it arises from plasma cell–derived monoclonal light chain deposition; it is associated with plasma cell dyscrasias.10 Given our patient's history of lymphoplasmacytic lymphoma, a diagnosis of AL amyloidosis was established. In AL amyloidosis with GI involvement, the amyloid deposition typically occurs in the muscularis mucosa, submucosa, and muscularis propria, resulting in protrusions and bowel obstruction.7 Amyloid deposits can also affect the GI neuromuscular layer, causing abnormal peristalsis and dysmotility.7 Common symptoms include abdominal pain, early satiety, weight loss, diarrhea, and constipation, while rare complications include pseudo-obstruction and protein-losing enteropathy.11 Symptom burden may vary by subtype, worsening with disease progression and improving with treatment.11 The patient presented with chronic abdominal pain, alternating diarrhea and constipation, and excessive flatulence. Further evaluation demonstrated protein-losing enteropathy, manifested by unintentional weight loss and new-onset lower extremity edema. Endoscopic features of AL amyloidosis include erythema, erosions, ulcers, granular mucosa, friability, and polypoid lesions.13 Biopsy is needed for diagnosis, but histology is often nonspecific; accurate subtype identification—preferably via proteomics—is essential for appropriate treatment.7,10,12 In this patient, biopsies were positive for amyloidosis; proteomic analysis was not performed, and the underlying diagnosis of lymphoplasmacytic lymphoma suggested AL amyloidosis. After diagnosing gastrointestinal amyloidosis, the key next step is amyloid subtyping as treatment differs by amyloid subtype (AL, ATTR, AA).14 Treatment of amyloidosis focuses on reducing the fibril precursor protein to slow amyloid formation and consists of a combination of chemotherapy, immunotherapy, and steroids.15 Management of gastrointestinal amyloidosis focuses on treating the underlying amyloid type, with supportive measures to alleviate specific gastrointestinal symptoms. Supportive treatment with dietary modification is a first-line strategy for managing dysmotility in gastrointestinal amyloidosis. Dietary measures consist of small, frequent meals of liquid or soft consistency; avoidance of fatty, spicy, acidic, and high-fiber foods; and consideration of a low-FODMAP diet to minimize gas production.16 In cases of protein-losing enteropathy, management should primarily target the underlying amyloid disease. When symptomatic therapy is warranted, first-line treatment includes opioid receptor agonists such as loperamide, with octreotide considered in refractory cases despite inconsistent evidence supporting its efficacy.16,17 The patient initiated chemotherapy with zanubrutinib for his underlying lymphoplasmacytic lymphoma. and was advised to adhere to a low FODMAP diet and implement a bowel regimen to address his gastrointestinal symptoms. The optimal number of biopsies and the role of endoscopic findings in diagnostic yield remain debated.13 Amyloid deposition along the GI tract varies by patient background and amyloidosis type. Duodenal and rectal biopsies show a high diagnostic yield regardless of biopsy number or endoscopic findings, whereas gastric biopsies have a lower yield, especially when endoscopic abnormalities are absent.11 In the patient's case, the histopathologic evaluation of gastric, duodenal, and jejunal biopsies revealed amyloid deposition. This case is of particular interest as it represents a rare and comprehensive presentation of GI amyloidosis secondary to lymphoplasmacytic lymphoma. It underscores the diagnostic challenge of identifying amyloidosis in patients initially presenting with chronic, nonspecific gastrointestinal symptoms. In contrast to most reported cases, the diagnosis in this patient was established through serial endoscopic evaluations and histopathologic correlation, offering a unique longitudinal perspective on disease progression and treatment response. DISCLOSURES Author contributions: S. Fansa and A. Ahmed conceived and designed the study. S. Fansa and A. Ahmed drafted the manuscript. All authors analyzed and interpreted the data. All authors critically revised the manuscript for intellectual content. All authors approved the final version of the manuscript. S. Fansa is the article guarantor. Financial disclosure: None to report. Informed consent was obtained for this case report.